-
Inhibikase Therapeutics NasdaqCM:IKT Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
Location: 3350 Riverwood Parkway SE, Atlanta, GA, 30339, United States | Website: https://www.inhibikase.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
61.52M
Cash
93.18M
Avg Qtr Burn
-4.846M
Short % of Float
5.56%
Insider Ownership
13.02%
Institutional Own.
74.02%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IkT-001Pro Details Cancer, Hematologic malignancies, Gastric cancer | Phase 3 Update | |
IkT-001 Details Pulmonary Arterial Hypertension (PAH) | Phase 2b Initiation | |
Risvodetinib (IkT-148009) Details Neurodegenerative disease, Parkinson's disease | Failed Discontinued |